| 0.042 -0.016 (-27.59%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.08 | 1-year : | 0.11 |
| Resists | First : | 0.07 | Second : | 0.1 |
| Pivot price | 0.05 |
|||
| Supports | First : | 0.02 | Second : | 0.02 |
| MAs | MA(5) : | 0.05 |
MA(20) : | 0.05  |
| MA(100) : | 0.23 |
MA(250) : | 0.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.5 |
D(3) : | 54.6 |
| RSI | RSI(14): 35.8 |
|||
| 52-week | High : | 1.26 | Low : | 0.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CARM ] has closed above bottom band by 10.4%. Bollinger Bands are 85.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.05 - 0.05 | 0.05 - 0.05 |
| Low: | 0.04 - 0.04 | 0.04 - 0.04 |
| Close: | 0.04 - 0.04 | 0.04 - 0.04 |
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Wed, 12 Nov 2025
Carisma Therapeutics Inc. SEC 10-Q Report - TradingView
Fri, 10 Oct 2025
Carisma Therapeutics stock plunges after Nasdaq delisting notice - Investing.com
Thu, 09 Oct 2025
Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension - TipRanks
Tue, 02 Sep 2025
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket - Benzinga
Mon, 23 Jun 2025
Carisma Therapeutics and OrthoCellix to Merge - citybiz
Mon, 23 Jun 2025
CARM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Carisma Therapeutics Inc. Is Fair to Shareholders - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 26.5 (%) |
| Held by Institutions | 17.6 (%) |
| Shares Short | 1,290 (K) |
| Shares Short P.Month | 787 (K) |
| EPS | -1.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.07 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0.36 |
| Forward Dividend | 0 |
| Dividend Yield | 855.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|